Reviva Pharmaceuticals Holdings, Inc. Common Stock (RVPH) Stock Price
RVPHStock
$0.46−95.56%52W
Market Cap$6.03M
P/E—
PEG Ratio—
Div yield—
Beta0.51
RVPH Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-101.86%
Price vs S&P 500 (4W)10.20%
VGM Score36.12
RVPH Earnings Surprise History
Q2 25-2.40est. -2.20
Q3 25-1.20est. -1.94
Q4 25-5.19est. -1.07
Q1 26-0.46est. -0.29
Q2 26-0.19est. -0.41
RVPH Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.08
4.08
4.00
4.00
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RVPHReviva Pharmaceuticals Holdings, Inc. Common Stock | — | — | D | $0.46 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Reviva Pharmaceuticals Holdings, Inc. Common Stock
Reviva Pharmaceuticals is a late-stage biopharmaceutical company developing therapeutics for central nervous system, inflammatory, and cardiometabolic diseases. Its lead candidate, Brilaroxazine (RP5063), targets multiple neuropsychiatric indications including schizophrenia, bipolar disorder, depression, ADHD, and dementia-related psychosis, with RP1208 also in development. The company uses a chemical genomics-driven platform and proprietary chemistry to discover and develop new medicines.